M. S. Nair

Persistence of an infectious form of SARS-CoV-2 post protease inhibitor treatment of permissive cells in vitro

The paper shows that an infectious intermediate form of SARS-CoV-2 persists in vitro after protease inhibitor treatment, potentially explaining viral rebound in patients.

Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking

This study identifies two antibodies that neutralize all SARS-CoV-2 variants by locking the spike protein in a down conformation, showing a novel mechanism and potential for prophylaxis.

Antibody avidity and multi-specificity combined to confer protection against SARS-CoV-2 and resilience against viral escape

This study develops a multimeric antibody platform (Multabody) that enhances neutralization potency and breadth against SARS-CoV-2 and its variants through avidity and multi-specificity.

SARS-CoV-2 omicron variants succumb in vitro to Artemisia annua hot water extracts

This study evaluates the in vitro antiviral efficacy of Artemisia annua hot water extracts against SARS-CoV-2 omicron variants and subvariants, finding IC50 values within assay variation limits.

Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2

This study shows that the Omicron variant of SARS-CoV-2 is highly resistant to neutralization by convalescent serum and vaccines, and many monoclonal antibodies.

Isolation and comparative analysis of antibodies that broadly neutralize sarbecoviruses

The paper identifies a human monoclonal antibody that neutralizes all tested sarbecoviruses and describes a new antibody class with potential for pandemic preparedness.

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses

This paper identifies a monoclonal antibody, 2-36, that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses, with a conserved epitope in the RBD identified through cryo-EM.

Artemisia annua hot-water extracts show potent activity in vitro against Covid-19 variants including delta

This study evaluates the anti-SARS-CoV-2 activity of Artemisia annua hot-water extracts against multiple variants, finding potent efficacy with low toxicity.

Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain

This paper reports the cryo-EM structure of antibody 5-7, which binds to a distinct site in the SARS-CoV-2 spike NTD, showing neutralization resistance to variants of concern.

Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike protein and the human ACE2 receptor

The paper predicts the effect of amino acid changes on SARS-CoV-2 spike protein binding to hACE2 using molecular dynamics and a neural network, achieving 82.2% classification accuracy and 0.69 correlation with experimental data.

Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates

A SARS-CoV-2 Spike ferritin nanoparticle vaccine induces broad neutralizing antibodies and protects nonhuman primates against respiratory infection and disease.

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization

This study shows the SARS-CoV-2 P.1 variant is more resistant to antibody neutralization than previous variants, but less affected by vaccine-induced immunity.

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

This study evaluates the neutralization resistance of SARS-CoV-2 variants B.1.1.7 and B.1.351 to monoclonal antibodies and sera, finding increased resistance in B.1.351.

Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite

This study identifies potent SARS-CoV-2 neutralizing antibodies targeting the N-terminal domain (NTD) and reveals they bind a common supersite on the spike protein.

Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants

This study shows that Artemisia annua extracts inhibit SARS-CoV-2 and its variants in vitro, with antiviral activity not linked to artemisinin or flavonoids, and suggests potential therapeutic use.

Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses

This study identifies a public antibody class, IGHV3-53/3-66, with potent SARS-CoV-2 neutralization capabilities through paired heavy and light chain interactions.

SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease

This study finds that patients with severe SARS-CoV-2 disease have higher antibody titers against viral proteins and neutralization capabilities compared to less severe cases.

Exploring the binding of resveratrol to an oncogene promoter DNA sequence d(CCAATTGG)2 through multispectroscopic, nuclear magnetic resonance and molecular dynamics studies

This study investigates resveratrol's binding to an oncogene promoter DNA sequence using spectroscopic and molecular dynamics methods, revealing it binds to the minor groove near AT basepairs.

A simplified cell-based assay to identify coronavirus 3CL protease inhibitors

This paper introduces a cell-based assay to identify coronavirus 3CL protease inhibitors without live virus, demonstrating its effectiveness through compound screening and structure-activity profiling.

Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

The paper identifies three structurally diverse compounds as inhibitors of the SARS-CoV-2 3CL protease and provides structural insights for inhibitor design.

Potent Neutralizing Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike

The paper isolates and characterizes 61 SARS-CoV-2-neutralizing monoclonal antibodies from infected patients, identifying potent antibodies targeting multiple epitopes on the spike protein.